Liver Disease in Urea Cycle Disorders
Learn more about:
Related Clinical Trial
Study for Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810
Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn
Hepatic Histopathology in Urea Cycle Disorders
Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency
Liver Disease in Urea Cycle Disorders
Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With OTC Deficiency
Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects
The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity
Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset OTC Deficiency
Neurologic Injuries in Adults With Urea Cycle Disorders
Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency
A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects
Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders
Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI
Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency
Phase I Study of Adenoviral Vector Mediated Gene Transfer for Ornithine Transcarbamylase in Adults With Partial Ornithine Transcarbamylase Deficiency
Phase I Pilot Study of Liver-Directed Gene Therapy for Partial Ornithine Transcarbamylase Deficiency